HK Stock Market Move | GUSHENGTANG (02273) surged over 11% with AI technology and OMO strategy empowering medical treatment. The company received a controlling stake from Ruiyuan Fund.

GUSHENGTANG (02273) rose by more than 11%, reaching 11.37% by the end of the report, at HK$38.7, with a turnover of HK$87.5872 million. On the news front, the latest information disclosed by the Hong Kong Stock Exchange shows that Ruiyuan Fund increased its holding of 410,000 shares of GUSHENGTANG on February 26, at a price of HK$38.6889 per share, with a total amount of approximately HK$15.8624 million. After the increase, the latest number of shares held is 14.7183 million, with a latest shareholding ratio of 6.04%. It is reported that Ruiyuan Fund increased its holding of 753,400 shares of GUSHENGTANG at an average price of HK$33.6615 per share on February 21, totaling about HK$25.3606 million. After the increase, the latest number of shares held by Ruiyuan Fund is 12.2049 million shares, and the shareholding ratio has increased from 4.7% to 5.01%. It is worth mentioning that on February 19, Goldman Sachs FICC and equity departments released a report on the "China AI Medical Index", and GUSHENGTANG was successfully selected for this list due to its advanced layout and innovative practices in the field of AI. Previously, GUSHENGTANG announced its access to DeepSeek. China Securities Co., Ltd. pointed out that in the future, the company will empower diagnosis and operation efficiency through: 1) AI technology and OMO strategy; 2) further expanding domestic and internationalization to enhance brand penetration; 3) driving transformation of traditional Chinese medicine intra-hospital preparations with digital intelligence. Currently, the company's valuation is at a historically low level, and it is optimistic about the company's performance maintaining a rapid growth trend and gradually realizing value revaluation.